Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 7:12:RP90948.
doi: 10.7554/eLife.90948.

Enhancing CRISPR prime editing by reducing misfolded pegRNA interactions

Affiliations

Enhancing CRISPR prime editing by reducing misfolded pegRNA interactions

Weiting Zhang et al. Elife. .

Abstract

CRISPR prime editing (PE) requires a Cas9 nickase-reverse transcriptase fusion protein (known as PE2) and a prime editing guide RNA (pegRNA), an extended version of a standard guide RNA (gRNA) that both specifies the intended target genomic sequence and encodes the desired genetic edit. Here, we show that sequence complementarity between the 5' and the 3' regions of a pegRNA can negatively impact its ability to complex with Cas9, thereby potentially reducing PE efficiency. We demonstrate this limitation can be overcome by a simple pegRNA refolding procedure, which improved ribonucleoprotein-mediated PE efficiencies in zebrafish embryos by up to nearly 25-fold. Further gains in PE efficiencies of as much as sixfold could also be achieved by introducing point mutations designed to disrupt internal interactions within the pegRNA. Our work defines simple strategies that can be implemented to improve the efficiency of PE.

Keywords: RNA structure; gene editing; genetics; genomics; protein delivery; zebrafish.

PubMed Disclaimer

Conflict of interest statement

WZ, JM, HL, CT, JY No competing interests declared, KP has a financial interest in SeQure Dx, Inc. KP's interests and relationships have been disclosed to Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies, JJ has, or had during the course of this research, financial interests in several companies developing gene editing technology: Beam Therapeutics, Blink Therapeutics, Chroma Medicine, Editas Medicine, EpiLogic Therapeutics, Excelsior Genomics, Hera Biolabs, Monitor Biotechnologies, Nvelop Therapeutics (f/k/a ETx, Inc), Pairwise Plants, Poseida Therapeutics, SeQure Dx, Inc, and Verve Therapeutics. JKJ's interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. JKJ is a co-inventor on various patents and patent applications that describe gene editing and epigenetic editing technologies

Figures

Figure 1.
Figure 1.. Improving in vitro SpCas9 binding efficiencies of pegRNA by refolding.
(a) Schematic illustrating the hybridization of a pegRNA and its target DNA. Four segments of a pegRNA are shown. PBS, Primer Binding Site; RTT, Reverse Transcriptase Template. Target DNA positions (as well as the corresponding sequences in the RTT) are numbered counting from the SpCas9-induced nick towards ‘NGG’, the protospacer adjacent motif (PAM). (b) Mutation frequencies induced by SpCas9 with gRNAs and pegRNAs in zebrafish. All pegRNAs carried a single nucleotide substitution at position +5 or+6, with RTT lengths of 14- or 15-nucleotide (nt), and PBS lengths of 10-nt (pegRNA-PBS10) or 13-nt (pegRNA-PBS13). Target loci are indicated at the bottom. SpCas9 protein was complexed with gRNA or pegRNA at a molar ratio of 1:2 (0.6 µM of gRNA or pegRNA). (c) Schematic illustrating hypothetical conformations of correctly folded and misfolded pegRNAs. The spacer is shown in green, Cas9-binding scaffold in orange and 3’ extension including PBS and RTT in blue. Dotted lines indicate potential base pairings. (d) Schematic illustrating the in vitro competition assay for Cas9 binding and substrate cleavage. Possible outcomes of the assay are shown in a representative gel. Lane 1 shows the addition of Competitor A with a high SpCas9-binding affinity resulting in 100% inhibition of cleavage of DNA substrates (1.2 kilobase pairs). Lane 2 shows the addition of Competitor B with a low SpCas9-binding affinity yielding a mix of uncleaved and cleaved (900 and 300 base pairs) DNA substrate. Lane 3 shows the reaction without any competitor resulting in 100% cleaved DNA products. (e) Agarose gel image showing the results of in vitro SpCas9 cleavage of DNA substrate in the presence of gRNA or pegRNAs targeting gpr78a as competitors, with or without refolding (indicated on top of the gel). Random RNA isolated from tolura yeast was used as a negative control. Assays were performed in triplicate. (f) Percentage of uncleaved DNA substrate in the presence or absence of competitor gRNA or pegRNA calculated using data from Figure 1—source data 1 and Figure 1—source data 2. Competitor gRNA and pegRNA target loci are indicated at the top. Competitor types are shown at the bottom. Dots represent individual data points, bars the mean and error bars ± s.e.m. Unpaired two-tailed t-test with equal variance was used to compare non-refolded gRNA vs non-refolded pegRNA, non-refolded pegRNA vs non-refolded pegRNA with three mutations in PBS, and non-refolded vs refolded pegRNAs. *p<0.05, **p<0.01, ***p<0.001.
Figure 1—figure supplement 1.
Figure 1—figure supplement 1.. Indel frequencies of non-refolded and refolded pegRNAs with SpCas9 in zebrafish.
Indel frequencies in zebrafish induced by SpCas9 complexed with non-refolded or refolded pegRNAs at a molar ratio of 1:2 (1.8 µM of pegRNA). Target loci, PBS lengths, and pegRNA-specified edits are indicated at the bottom. Dots represent individual data points (n=3 biologically independent replicates, 5–10 embryos per replicate), bars the mean and error bars ± s.e.m. Results of unpaired two-tailed t-test with equal variance are shown in *p<0.05, **p<0.01, ***p<0.001.
Figure 2.
Figure 2.. Improving prime editing efficiencies in zebrafish by pegRNA refolding and mutations in RTT.
(a–b) Pure PE frequencies of non-refolded and refolded substitution pegRNAs (a) and insertion or deletion pegRNAs (b) with PE2 in zebrafish. Target loci, PBS lengths (labeled as ‘P’ followed by the number of nucleotides), RTT lengths (labeled as ‘R’ followed by the number of nucleotides), and pegRNA-specified edits (denoted as the position of the edit followed by the edit) are shown at the top. Pure PE represents sequencing reads containing only the pegRNA-specified mutations. (c–d) Pure PE frequencies with refolded pegRNAs carrying additional RTT mutations (at +1,+2 or+3) and PE2 in zebrafish. Target loci, PBS, and RTT lengths are shown at the top and pegRNA-specified edits are shown at the bottom. All pegRNAs had 3 or 4 thymine (T) nucleotides at the 3’ end except for the ones labeled ‘A end’ for scn2b in which the terminal Ts were replaced with adenine (A) nucleotides. Dots represent individual data points (n=3 biologically independent replicates, 5–10 embryos per replicate), bars the mean and error bars ± s.e.m. *p<0.05, **p<0.01, ***p<0.001 (unpaired two-tailed t-test with equal variance).
Figure 2—figure supplement 1.
Figure 2—figure supplement 1.. Purities of prime editing with PE2 and non-refolded or refolded pegRNAs in zebrafish.
(a–b) Frequencies of non-pure PE edits (labeled as other edits) mediated by PE2 with non-refolded and refolded substitution pegRNAs (a) and insertion or deletion pegRNAs (b). (c–d) PE purities (%) calculated as pure PE over total edit (pure and non-pure PE) frequencies for substitution pegRNAs (c) and insertion or deletion pegRNAs (d). Target loci, PBS lengths (labeled as ‘P’ followed by the number of nucleotides), RTT lengths (labeled as ‘R’ followed by the number of nucleotides), and pegRNA-specified edits are indicated at the top. Dots represent individual data points (n=3 biologically independent replicates, 5–10 embryos per replicate), bars the mean and error bars ± s.e.m. Results of unpaired two-tailed t-test with equal variance are shown in *p<0.05, **p<0.01, ***p<0.001.
Figure 2—figure supplement 2.
Figure 2—figure supplement 2.. Purities of prime editing with PE2 and refolded pegRNAs carrying additional RTT mutations in zebrafish.
(a–b) Frequencies of non-pure PE edits (labeled as other edits) mediated by PE2 with refolded pegRNAs with or without an additional mutation in the RTT (at +1,+2 or+3). (c) PE purities calculated as pure PE over total edit (pure and non-pure PE) frequencies. Target loci, PBS lengths (labeled as ‘P’ followed by the number of nucleotides), and RTT lengths (labeled as ‘R’ followed by the number of nucleotides) are shown at the top. pegRNA-specified edits (denoted as the position of the edit followed by the edit) are shown at the bottom. Dots represent individual data points (n=3 biologically independent replicates, 5–10 embryos per replicate), bars the mean, error bars ± s.e.m. Results of unpaired two-tailed t-test with equal variance are shown in *p<0.05, **p<0.01, ***p<0.001.
Figure 2—figure supplement 3.
Figure 2—figure supplement 3.. Indel frequencies in zebrafish induced by SpCas9 complexed with refolded pegRNAs with or without RTT mutation at +2 position.
SpCas9 protein and pegRNA were combined at a molar ratio of 1:2. (1.8 µM of pegRNA). Target loci, PBS lengths (labeled as ‘P’ followed by the number of nucleotides), and RTT lengths (labeled as ‘R’ followed by the number of nucleotides) are shown at the top. pegRNA-specified edits (denoted as the position of the edit followed by the edit) are shown at the bottom. Dots represent individual data points (n=3 biologically independent replicates, 5–10 embryos per replicate), bars the mean and error bars ± s.e.m. Results of unpaired two-tailed t-test with equal variance are shown in **p<0.01.

Update of

Similar articles

Cited by

References

    1. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A, Liu DR. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149–157. doi: 10.1038/s41586-019-1711-4. - DOI - PMC - PubMed
    1. Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nature Biotechnology. 2020;38:824–844. doi: 10.1038/s41587-020-0561-9. - DOI - PubMed
    1. Bosch JA, Birchak G, Perrimon N. Precise genome engineering in Drosophila using prime editing. PNAS. 2021;118:e2021996118. doi: 10.1073/pnas.2021996118. - DOI - PMC - PubMed
    1. Burger A, Lindsay H, Felker A, Hess C, Anders C, Chiavacci E, Zaugg J, Weber LM, Catena R, Jinek M, Robinson MD, Mosimann C. Maximizing mutagenesis with solubilized CRISPR-Cas9 ribonucleoprotein complexes. Development. 2016;143:2025–2037. doi: 10.1242/dev.134809. - DOI - PubMed
    1. Clement K, Rees H, Canver MC, Gehrke JM, Farouni R, Hsu JY, Cole MA, Liu DR, Joung JK, Bauer DE, Pinello L. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nature Biotechnology. 2019;37:224–226. doi: 10.1038/s41587-019-0032-3. - DOI - PMC - PubMed

MeSH terms

Substances